SEQUENCE LISTING

<110> FAIRLIE, DAVID
MAXWELL, STEPHEN
FINCH, ANGELA MONIQUE
WONG, ALLAN

<120> CYCLIC ANGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PR
OTEIN-COUPLED RECEPTORS

<130> 10648-0001-0PCT

<140> 09/446,109
<141> 2000-04-21

<150> PCT/AU98/00490
<151> 1998-06-25

<150> AU P07550
<151> 1997-06-25

<160> 24

<170> PatentIn version 3.1

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<400> 1

Ile Ser His Lys Asp Met Gln Leu Gly Arg
1   5   10

<210> 2
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<400> 2

Tyr Ser Phe Lys Asp Met Gln Leu Gly Arg
1   5   10

```
<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is D-Ala

<400>  3

Tyr Ser Phe Lys Asp Met Pro Leu Xaa Arg
1               5                   10


<210>  4
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa is D-Ala

<400>  4

Tyr Ser Phe Lys Pro Met Pro Leu Xaa Arg
1               5                   10


<210>  5
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<220>
<221>  misc_feature
<222>  (11)..(11)
```

<223> MOD_RES: Acp

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa is D-Ala

<400> 5

Arg Ala Ala Arg Ile Ser Leu Gly Pro Arg Xaa Tyr Ser Phe Lys Pro
1   5   10   15

Met Pro Leu Xaa Arg
            20

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> misc_feature
<222> (10)..(10)
<223> MOD_RES: Acp

<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa is D-Ala

<400> 6

Lys Tyr Lys His Ser Val Val Lys Lys Xaa Tyr Ser Phe Lys Pro Met
1   5   10   15

Pro Leu Xaa Arg
            20

<210> 7
<211> 6
<212> PRT

<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> METHYLATION

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa is D-cyclohexylalanine

<400> 7

Phe Lys Pro Xaa Trp Arg
1   5

<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> METHYLATION

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa is D-cyclohexylalanine

<220>
<221> MOD_RES
<222> (6)..(6)
<223> residue is substituted with (CO)NH2

<400> 8

Phe Lys Pro Xaa Trp Arg

1   5

<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> METHYLATION

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa is D-cylcohexylalanine

<400> 9

Phe Lys Pro Xaa Trp Arg
1   5

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> METHYLATION

<400> 10

Phe Lys Pro Leu Trp Arg
1   5

<210> 11
<211> 6
<212> PRT

<213>   Artificial Sequence

<220>
<223>   synthetic peptide

<220>
<221>   SITE
<222>   (2)..(6)
<223>   cyclic portion

<220>
<221>   MOD_RES
<222>   (1)..(1)
<223>   ACETYLATION

<220>
<221>   misc_feature
<222>   (4)..(4)
<223>   Xaa is D-cylcohexylalanine

<400>   11

Phe Lys Pro Xaa Trp Arg
1   5

<210>   12
<211>   6
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   synthetic peptide

<220>
<221>   MOD_RES
<222>   (1)..(1)
<223>   ACETYLATION

<220>
<221>   misc_feature
<222>   (2)..(2)
<223>   Orn

<220>
<221>   misc_feature
<222>   (4)..(4)

<223> D-cyclohexylalanine

<220>
<221> SITE
<222> (2)..(6)
<223> cyclic portion

<400> 12

Phe Xaa Pro Xaa Trp Arg
1   5

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> SITE
<222> (1)..(2)
<223> between residues 1 and 2: (CH2)-NH2

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa is D-cyclohexylalanine

<220>
<221> SITE
<222> (1)..(5)
<223> cyclic portion is from residue 5 and the (CH2) NH2 moiety
present
        between residues 1 and 2

<400> 13

Phe Pro Xaa Trp Arg
1   5

<210> 14
<211> 5
<212> PRT

<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa is D-cyclohexylalanine

<220>
<221> misc_feature
<222> (1)..(2)
<223> between residues 1 and 2: (CH2)-NH2

<220>
<221> SITE
<222> (1)..(5)
<223> cyclic portion is from residue 5 and the (CH2)-NH2 moiety between
        residues 1 and 2

<400> 14

Phe Pro Xaa Trp Arg
1   5

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> misc_feature
<222> (1)..(2)
<223> between residues 1 and 2: (CH2)2-NH2

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa is D-cyclohexylalanine

<220>

<221> SITE
<222> (1)..(5)
<223> cyclic portion is from residue 5 and the (CH2)2-NH2 moiety
 betwee
       n residues 1 and 2

<400> 15

Phe Pro Xaa Trp Arg
1   5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> misc_feature
<222> (1)..(2)
<223> between residues 1 and 2: (CH2)2-NH2

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa is D-cyclohexylalanine

<220>
<221> SITE
<222> (1)..(5)
<223> cyclic portion is from residue 5 and the (CH2)2-NH2 moiety
 betwee
       n residues 1 and 2

<400> 16

Phe Pro Xaa Trp Arg
1   5

<210> 17
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa is Orn

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa is D-cyclohexylalanine

<220>
<221> misc_feature
<222> (2)..(6)
<223> cyclic portion

<400> 17

Phe Xaa Pro Xaa Trp Arg
1   5

<210> 18
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> misc_feature
<222> (2)..(2)
<223> Orn

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa is D-cyclohexylalanine

<220>
<221> SITE
<222> (2)..(6)
<223> cyclic portion

<400> 18

Phe Xaa Pro Xaa Trp Arg
1   5

<210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa is D-cyclohexylalanine

<220>
<221> SITE
<222> (1)..(6)
<223> cyclic portion

<400> 19

Phe Trp Pro Xaa Trp Arg
1   5

<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide

```
<220>
<221>   MOD_RES
<222>   (1)..(1)
<223>   ACETYLATION


<220>
<221>   misc_feature
<222>   (4)..(4)
<223>   Xaa is D-cyclohexylalanine


<220>
<221>   SITE
<222>   (2)..(6)
<223>   cyclic portion


<400>   20

Phe Lys Met Xaa Trp Arg
1               5


<210>   21
<211>   6
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   synthetic peptide

<220>
<221>   MOD_RES
<222>   (1)..(1)
<223>   ACETYLATION


<220>
<221>   misc_feature
<222>   (4)..(4)
<223>   Xaa is D-cyclohexylalanine


<220>
<221>   SITE
<222>   (2)..(6)
<223>   cyclic portion


<400>   21
```

Phe Lys Lys Xaa Trp Arg
1   5

<210>   22
<211>   5
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   synthetic peptide

<220>
<221>   MOD_RES
<222>   (1)..(1)
<223>   ACETYLATION

<220>
<221>   SITE
<222>   (2)..(2)
<223>   Xaa is (CH2)-NH2

<220>
<221>   misc_feature
<222>   (3)..(3)
<223>   Xaa is D-cyclohexylalanine

<220>
<221>   SITE
<222>   (1)..(5)
<223>   cyclic portion is from residue 5 and the (CH2)-NH2 moiety
between
        residues 1 and 2

<400>   22

Phe Pro Xaa Trp Arg
1   5

<210>   23
<211>   5
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   synthetic peptide

```
<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION


<220>
<221>  SITE
<222>  (1)..(2)
<223>  between residues 1 and 2: (CH2)-NH2


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  residue is D-cyclohexylalanine


<220>
<221>  SITE
<222>  (1)..(5)
<223>  cyclic portion is from residue 5 and the (CH2)2-NH2 moiety
 betwee
        n residues 1 and 2


<400>  23

Phe Pro Xaa Trp Arg
1               5


<210>  24
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Orn
```

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa is D-cyclohexylalanine

<220>
<221> SITE
<222> (3)..(7)
<223> cyclic portion

<400> 24

Lys Phe Xaa Pro Xaa Trp Arg
1   5